

## **CERTIFICATE OF ANALYSIS No.: 2025-16164**

## CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

## SAMPLE \*

DR KENT GLUCOSAMINE CBD CREAM



	1	

Sample condition: SUITABLE Work order: 2025-112629 Sample received: 20/02/2025 2508041 Sample ID: Analysis ID: 2025\_052 Start of analysis: 20/02/2025 Sample type: Method ID: PHL\_RPC\_16C End of analysis: 20/02/2025 Cream Batch No.: \* KCG01125050A Method SOP: MET-LAB-001-08 Analyst: Valentina Malin \* Information provided by the client.

CANNABINOID PROFILE		Concentration [% w/w]	Expanded uncertainty [% w/w]	Graphic presentation of relative cannabinoid concentration
CBDV	- Cannabidivarin	< LOQ	n/a	
CBDA	- Cannabidiolic acid	< LOQ	n/a	
CBGA	- Cannabigerolic acid	< LOQ	n/a	
CBG	- Cannabigerol	< LOQ	n/a	
CBD	- Cannabidiol	1.128	0.056	
тнсу	- Tetrahydrocannabivarin	< LOQ	n/a	
CBN	- Cannabinol	< LOQ	n/a	
∆ <sup>9</sup> -THC	- Δ-9-Tetrahydrocannabinol	0.047	0.010	
∆ <sup>8</sup> -THC	- Δ-8-Tetrahydrocannabinol	< LOQ	n/a	
CBL	- Cannabicyclol	< LOQ	n/a	
СВС	- Cannabichromene	< LOQ	n/a	
∆ <sup>9</sup> -THCA	- Δ-9-Tetrahydrocannabinolic acid	< LOQ	n/a	
СВУ	- Cannabivarin	< LOQ	n/a	
СВСА	- Cannabichromenic acid	< LOQ	n/a	
СВТ	- Cannabicitran	< LOQ	n/a	
CBE	- Cannabielsoin	< LOQ	n/a	

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received and tested. **Expanded Uncertainty** was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit from PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

Approved by:

20/02/2025

End of Certificate

mag. Valentina Malin Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar Chief Technology Officer